Coloplast A/S Sponsored ADR (CLPBY)
(Delayed Data from OTC)
$13.02 USD
+0.12 (0.89%)
Updated Jul 24, 2024 03:59 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Coloplast AS Sponsored ADR falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 131 | 92 | 108 | 88 | 101 |
Receivables | 734 | 679 | 598 | 528 | 541 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 505 | 465 | 390 | 335 | 292 |
Other Current Assets | 55 | 43 | 28 | 24 | 27 |
Total Current Assets | 1,425 | 1,279 | 1,124 | 975 | 961 |
Net Property & Equipment | 736 | 652 | 608 | 497 | 491 |
Investments & Advances | 9 | 7 | 7 | 4 | 1 |
Other Non-Current Assets | 6 | 5 | 4 | 4 | 4 |
Deferred Charges | 127 | 98 | 119 | 100 | 89 |
Intangibles | 4,482 | 2,956 | 587 | 355 | 378 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 6,906 | 5,097 | 2,546 | 2,028 | 1,924 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 186 | 181 | 166 | 122 | 130 |
Current Portion Long-Term Debt | 695 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 606 | 196 | 149 | 151 | 161 |
Other Current Liabilities | 819 | 662 | 671 | 444 | 454 |
Total Current Liabilities | 2,339 | 1,070 | 1,015 | 748 | 747 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1,657 | 2,385 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 334 | 361 | 146 | 103 | 112 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4,425 | 3,888 | 1,233 | 915 | 879 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 33 | 31 | 35 | 32 | 33 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | 2,098 | 785 | 869 | 712 | 661 |
Other Equity | 350 | 392 | 409 | 368 | 351 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 2,481 | 1,209 | 1,313 | 1,112 | 1,045 |
Total Liabilities & Shareholder's Equity | 6,906 | 5,097 | 2,546 | 2,028 | 1,924 |
Total Common Equity | 2,481 | 1,209 | 1,313 | 1,112 | 1,045 |
Shares Outstanding | NA | NA | 2,160.00 | 2,160.00 | 2,160.00 |
Book Value Per Share | -0.02 | -0.01 | 0.61 | 0.51 | 0.48 |
Fiscal Year End for Coloplast AS Sponsored ADR falls in the month of September.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 129 | 132 | 131 | 125 |
Receivables | NA | 808 | 757 | 734 | 715 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 519 | 508 | 505 | 520 |
Other Current Assets | NA | 56 | 57 | 55 | 54 |
Total Current Assets | NA | 1,513 | 1,454 | 1,425 | 1,413 |
Net Property & Equipment | NA | 778 | 756 | 736 | 722 |
Investments & Advances | NA | 11 | 9 | 9 | 10 |
Other Non-Current Assets | NA | 5 | 5 | 6 | 5 |
Deferred Charges | NA | 133 | 132 | 127 | 97 |
Intangibles | NA | 4,427 | 4,540 | 4,482 | 2,755 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 7,009 | 7,017 | 6,906 | 5,126 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 179 | 168 | 186 | 156 |
Current Portion Long-Term Debt | NA | 706 | 700 | 695 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 194 | 668 | 606 | 221 |
Other Current Liabilities | NA | 1,405 | 1,163 | 819 | 1,028 |
Total Current Liabilities | NA | 2,520 | 2,732 | 2,339 | 1,437 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 1,683 | 1,668 | 1,657 | 2,394 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 338 | 334 | 248 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 4,650 | 4,832 | 4,425 | 4,178 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 33 | 33 | 33 | 32 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | 2,377 | 2,301 | 2,098 | 1,151 |
Other Equity | NA | -51 | -150 | 350 | -234 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 2,359 | 2,184 | 2,481 | 948 |
Total Liabilities & Shareholder's Equity | NA | 7,009 | 7,017 | 6,906 | 5,126 |
Total Common Equity | 0 | 2,359 | 2,184 | 2,481 | 948 |
Shares Outstanding | NA | NA | NA | NA | NA |
Book Value Per Share | 0.00 | -0.02 | -0.02 | -0.02 | -0.01 |